You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

3 Results
Drug
Other Name(s): Rydapt®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jun 2025
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
  • melphalan - oral tablets
ODB - General Benefit
  • prednisone
Exceptional Access Program
  • thalidomide - Multiple myeloma in patients ≥65 years of age in combination with melphalan and prednisone, with specific criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
melphalan,
prednisone,
thalidomide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2019
Regimen
Cancer Type:
Hematologic, 
Myelofibrosis
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    momelotinib - For the treatment of splenomegaly and/or disease-related symptoms of myelofibrosis, according to specific criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
momelotinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
New
Apr 2026